ADVICENNE Revenue and Competitors
Estimated Revenue & Valuation
- ADVICENNE's estimated annual revenue is currently $6.2M per year.
- ADVICENNE's estimated revenue per employee is $201,000
Employee Data
- ADVICENNE has 31 Employees.
- ADVICENNE grew their employee count by 3% last year.
ADVICENNE's People
Name | Title | Email/Phone |
---|---|---|
1 | General Manager USA | Reveal Email/Phone |
ADVICENNE Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is ADVICENNE?
Advicenne Pharma SA is a pharmaceuticals company based out of France.
keywords:N/AN/A
Total Funding
31
Number of Employees
$6.2M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ADVICENNE News
2022-04-19 - GABA Receptor Agonist Drug Market 2022 Innovative Strategy ...
Advicenne; AstraZeneca; Athena Drug Delivery Solutions; Biocodex; Elan Corporation; Eli Lilly and Company; H.LundBeck Merck and Co...
2022-03-30 - Advicenne announces the transfer of its shares from Euronext ...
Advicenne (Paris:ADVIC), a pharmaceutical company specializing in the development and commercialization of innovative treatments for people...
2022-03-30 - ERRATUM - Advicenne Reports its Financial Results for the ...
Advicenne (Paris:ALDVI) (Euronext: ALDVI), a pharmaceutical company specializing in the development and commercialization of innovative...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.7M | 31 | 7% | N/A |
#2 | $3.6M | 31 | -14% | N/A |
#3 | $4.5M | 31 | -14% | N/A |
#4 | $6.7M | 31 | -11% | N/A |
#5 | $6.7M | 31 | 3% | N/A |